Regeneron Pharmaceuticals

At a glance

Regeneron Pharmaceuticals reported 2025 revenue of $14.34B, up 1% from $14.2B in 2024. Over 4 years since 2021 ($16.07B), that is a decline of about 2.8% a year. Operating margin was 24.9%, down from 55.7% in 2021. Revenue peaked in 2021 at $16.07B.

In the last 12 months 7 insiders reported 0 open-market purchases and 15 sales ($11.9M). 14 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $3.2M by Co-Chief Scientific Officer Andrew J Murphy on Oct 15, 2026.

Regeneron Pharmaceuticals filed 10 current reports (Form 8-K) in the last 12 months, most often for results of operations (8), material agreement (1), officer or director change (1) and shareholder vote results (1). The latest officer or director change was reported on Sep 30, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.

3 of the 20 investors tracked here held Regeneron Pharmaceuticals at the last quarter end, worth $361.3M combined. It is the largest weight for National Pension Service (Korea) (0.2% of its portfolio), followed by Bridgewater Associates (0.1%). Added: National Pension Service (Korea), Bridgewater Associates and Renaissance Technologies.

Annual results

Fiscal year ends Dec 31 · incorporated in NY

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.